RYCPX Performance — Consumer Products Fund, Class C
Data updated: 2026-08-28
RYCPX returned +6.14% year to date and −0.54% over one year to Jun 2026. Annualised returns are +0.58% over 3 years and +0.70% over 5 years. The fund trailed its Consumer Staples Equity category average: $100 invested three years ago grew to $102, against $112 for the category, and to $99 over one year, against $104. Volatility over the past three years was 12.70% a year. In the 12 months to Jun 2026 the fund lost a net $3.4M, and assets reached $30.18M.
RYCPX Growth of $100
What $100 invested in Consumer Products Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Consumer Staples Equity category average over the same months.
| Period | RYCPX | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $99 | $104 |
| 3 years (Jul 2023 – Jun 2026) | $102 | $112 |
| 5 years (Jul 2021 – Jun 2026) | $104 | $120 |
| Since data start (Jul 2019 – Jun 2026) | $128 | $161 |
RYCPX Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +6.14% |
| 1 year | −0.54% |
| 3 years (annualised) | +0.58% |
| 5 years (annualised) | +0.70% |
RYCPX Annual Returns
Calendar-year total returns of Consumer Products Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +6.14% |
| 2025 | −3.87% |
| 2024 | +3.89% |
| 2023 | −3.81% |
| 2022 | −1.40% |
| 2021 | +10.01% |
| 2020 | +7.20% |
| 2019 (Jul–Dec) | +7.83% |
RYCPX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +6.4% | +6.8% | −10.6% | +2.9% | −1.2% | +2.8% | — | — | — | — | — | — |
| 2025 | −0.4% | +3.2% | +1.0% | −0.7% | +0.9% | −1.3% | −1.0% | +1.5% | −4.1% | −3.4% | +2.9% | −2.2% |
| 2024 | −0.3% | +2.4% | +3.9% | −1.9% | +0.3% | −2.0% | +2.7% | +4.2% | +0.8% | −3.7% | +3.7% | −5.8% |
| 2023 | +0.1% | −2.4% | +2.9% | +3.1% | −6.1% | +3.1% | +1.6% | −3.6% | −5.1% | −3.6% | +4.4% | +2.6% |
| 2022 | −1.5% | −0.2% | +0.4% | +1.8% | −1.9% | −3.3% | +3.0% | −1.7% | −9.1% | +9.7% | +5.3% | −2.5% |
| 2021 | −3.3% | +0.6% | +7.3% | +2.5% | +1.6% | −1.9% | −0.9% | −0.3% | −4.1% | +1.9% | −3.0% | +10.0% |
| 2020 | −1.1% | −8.5% | −8.6% | +8.9% | +2.8% | 0.0% | +6.4% | +4.0% | −3.0% | −3.2% | +8.8% | +2.5% |
| 2019 | — | — | — | — | — | — | +1.8% | +0.8% | +1.7% | −1.6% | +2.3% | +2.8% |
RYCPX Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 12.70%
- 3-year Sharpe ratio: -0.31 (vs 4.5% risk-free rate)
- Best month: +6.81% (Feb 2026)
- Worst month: −10.56% (Mar 2026)
RYCPX Fund Flows
Monthly money in and out of Consumer Products Fund, from SEC Form N-PORT.
- 12-month net flow: −$3.4M
- 12-month gross sales (incl. reinvestments): $19.5M
- Sales ÷ redemptions: 0.85×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $399K | $1.3M | −$907K |
| May 2026 | $905K | $1.2M | −$276K |
| Apr 2026 | $259K | $1.8M | −$1.5M |
| Mar 2026 | $1.5M | $1.5M | $14K |
| Feb 2026 | $1.5M | $1.5M | −$21K |
| Jan 2026 | $3.3M | $1.8M | $1.5M |
| Dec 2025 | $5.5M | $4.2M | $1.4M |
| Nov 2025 | $722K | $1.2M | −$484K |
| Oct 2025 | $548K | $1.2M | −$696K |
| Sep 2025 | $230K | $1.2M | −$989K |
| Aug 2025 | $1.2M | $1.8M | −$524K |
| Jul 2025 | $3.4M | $4.2M | −$811K |
RYCPX Assets Under Management
Net assets of Consumer Products Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $30.18M |
| 2026-03-31 | $31.52M |
| 2025-12-31 | $29.38M |
| 2025-09-30 | $34.94M |
| 2025-06-30 | $38.43M |
| 2025-03-31 | $40.61M |
| 2024-12-31 | $45.63M |
| 2024-09-30 | $54.68M |
| 2024-06-30 | $54.07M |
| 2024-03-31 | $61.75M |
| 2023-12-31 | $55.93M |
| 2023-09-30 | $61.47M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.